[Epstein-Barr virus-associated posttransplant lymphoproliferative disease after renal transplantation]. 2002

Etsuko Matsubara, and Yoshihiro Yakushijin, and Tetsuhiko Nomura, and Kikue Iwamasa, and Hiroshi Narumi, and Ikuya Sakai, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Koichi Ohshima, and Masatoshi Uno
First Department of Internal Medicine, Ehime University School of Medicine, Ehime, Japan.

A 24-year-old Japanese male was admitted to our hospital because of lymphadenopathy in his left neck. He had a nine-year history of chronic renal failure, and had received an ABO-mismatched renal allograft and splenectomy in August 2000 after one year of hemodialysis treatment. After renal transplantation, he was treated with FK506, methylprednisolone (mPSL), and mycophenolate mofetil (MMF) as an immunosuppressants for his graft maintenance. On admission, April 2001, he underwent lymphadenectomy, and the immunohistochemical studies revealed that the tumor cells expressed EBV-LMP and EBNA-2 antigens with the histology of diffuse large B-cell lymphoma. Our diagnosis was an Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disease (PTLD), and we reduced the dose of immunosuppressive agents and treated the patient with rituximab. In this case, there may have been two principal risk factors associated with PTLD: first, the patient was treated with higher levels of immunosuppressive agents because of the ABO-mismatched transplantation, and second, he was an EBV-seronegative recipient at the time of pretransplantation.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008232 Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified. Duncan's Syndrome,X-Linked Lymphoproliferative Syndrome,Duncan Disease,Epstein-Barr Virus Infection, Familial Fatal,Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males,Familial Fatal Epstein-Barr Infection,Immunodeficiency 5,Immunodeficiency, X-Linked Progressive Combined Variable,Lymphoproliferative Disease, X-Linked,Lymphoproliferative Syndrome, X-Linked, 1,Purtilo Syndrome,X-Linked Lymphoproliferative Disease,X-Linked Lymphoproliferative Disorder,Disease, Duncan,Disease, X-Linked Lymphoproliferative,Diseases, X-Linked Lymphoproliferative,Disorder, Lymphoproliferative,Disorder, X-Linked Lymphoproliferative,Disorders, Lymphoproliferative,Disorders, X-Linked Lymphoproliferative,Epstein Barr Virus Induced Lymphoproliferative Disease In Males,Epstein Barr Virus Infection, Familial Fatal,Familial Fatal Epstein Barr Infection,Immunodeficiency 5s,Immunodeficiency, X Linked Progressive Combined Variable,Lymphoproliferative Disease, X Linked,Lymphoproliferative Diseases, X-Linked,Lymphoproliferative Disorder,Lymphoproliferative Disorder, X-Linked,Lymphoproliferative Disorders, X-Linked,Lymphoproliferative Syndrome, X-Linked,Lymphoproliferative Syndromes, X-Linked,Purtilo Syndromes,Syndrome, Purtilo,Syndrome, X-Linked Lymphoproliferative,Syndromes, Purtilo,Syndromes, X-Linked Lymphoproliferative,X Linked Lymphoproliferative Disease,X Linked Lymphoproliferative Disorder,X Linked Lymphoproliferative Syndrome,X-Linked Lymphoproliferative Diseases,X-Linked Lymphoproliferative Disorders,X-Linked Lymphoproliferative Syndromes
D008297 Male Males
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D001787 Blood Group Incompatibility An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984). ABO Compatibility,ABO Incompatibility,Blood Group ABO Incompatibility,Blood Type Incompatibility,Rh Compatibility,Rh Incompatibility,ABO Compatibilities,ABO Incompatibilities,Blood Group Incompatibilities,Blood Type Incompatibilities,Compatibility, ABO,Compatibility, Rh,Incompatibilities, Blood Group,Incompatibility, ABO,Incompatibility, Blood Group,Incompatibility, Blood Type,Incompatibility, Rh,Rh Compatibilities,Rh Incompatibilities
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000017 ABO Blood-Group System The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane. ABH Blood Group,ABO Blood Group,ABO Factors,Blood Group H Type 1 Antigen,H Blood Group,H Blood Group System,ABO Blood Group System,Blood Group, ABH,Blood Group, ABO,Blood Group, H,Blood-Group System, ABO,Factors, ABO,System, ABO Blood-Group
D000069283 Rituximab A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. CD20 Antibody, Rituximab,GP2013,IDEC-C2B8,IDEC-C2B8 Antibody,Mabthera,Rituxan,IDEC C2B8,IDEC C2B8 Antibody,Rituximab CD20 Antibody
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

Etsuko Matsubara, and Yoshihiro Yakushijin, and Tetsuhiko Nomura, and Kikue Iwamasa, and Hiroshi Narumi, and Ikuya Sakai, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Koichi Ohshima, and Masatoshi Uno
October 1996, Transplantation proceedings,
Etsuko Matsubara, and Yoshihiro Yakushijin, and Tetsuhiko Nomura, and Kikue Iwamasa, and Hiroshi Narumi, and Ikuya Sakai, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Koichi Ohshima, and Masatoshi Uno
November 2014, Current opinion in oncology,
Etsuko Matsubara, and Yoshihiro Yakushijin, and Tetsuhiko Nomura, and Kikue Iwamasa, and Hiroshi Narumi, and Ikuya Sakai, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Koichi Ohshima, and Masatoshi Uno
October 2001, Journal of pediatric gastroenterology and nutrition,
Etsuko Matsubara, and Yoshihiro Yakushijin, and Tetsuhiko Nomura, and Kikue Iwamasa, and Hiroshi Narumi, and Ikuya Sakai, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Koichi Ohshima, and Masatoshi Uno
January 2019, Clinical medicine insights. Case reports,
Etsuko Matsubara, and Yoshihiro Yakushijin, and Tetsuhiko Nomura, and Kikue Iwamasa, and Hiroshi Narumi, and Ikuya Sakai, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Koichi Ohshima, and Masatoshi Uno
December 2001, Transplantation,
Etsuko Matsubara, and Yoshihiro Yakushijin, and Tetsuhiko Nomura, and Kikue Iwamasa, and Hiroshi Narumi, and Ikuya Sakai, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Koichi Ohshima, and Masatoshi Uno
May 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
Etsuko Matsubara, and Yoshihiro Yakushijin, and Tetsuhiko Nomura, and Kikue Iwamasa, and Hiroshi Narumi, and Ikuya Sakai, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Koichi Ohshima, and Masatoshi Uno
November 2004, Journal of the American Academy of Dermatology,
Etsuko Matsubara, and Yoshihiro Yakushijin, and Tetsuhiko Nomura, and Kikue Iwamasa, and Hiroshi Narumi, and Ikuya Sakai, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Koichi Ohshima, and Masatoshi Uno
January 2001, Journal of pediatric hematology/oncology,
Etsuko Matsubara, and Yoshihiro Yakushijin, and Tetsuhiko Nomura, and Kikue Iwamasa, and Hiroshi Narumi, and Ikuya Sakai, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Koichi Ohshima, and Masatoshi Uno
June 1990, Transplantation,
Etsuko Matsubara, and Yoshihiro Yakushijin, and Tetsuhiko Nomura, and Kikue Iwamasa, and Hiroshi Narumi, and Ikuya Sakai, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Koichi Ohshima, and Masatoshi Uno
August 1992, Anales espanoles de pediatria,
Copied contents to your clipboard!